Skip to Main Content


Over 10 million Americans are cancer survivors. The vast majority of these people will bear some mark of their cancer and/or its treatment, and a large proportion will experience long-term consequences that include medical problems, psychosocial dysfunction, economic hardship, sexual dysfunction, and discrimination in employment and insurance. Many of these problems are directly related to cancer treatment. As patients with more types of malignancies survive longer, the biologic toll that very imperfect therapies take in terms of morbidity and mortality rates is being recognized increasingly. These consequences of therapy confront the patients and the cancer specialists and general internists who manage them every day. Although long-term survivors of childhood leukemias, Hodgkin's lymphoma, and testicular cancer have increased knowledge about the consequences of cancer treatment, researchers and physicians keep learning more as patients survive longer with newer therapies. The pace of the development of therapies that mitigate treatment-related consequences has been slow, partly due to an understandable aversion to altering regimens that work and partly due to a lack of new, effective, less toxic therapeutic agents with less "collateral damage" to replace known agents with known toxicities. The types of damage from cancer treatment vary. Often, a final common pathway is irreparable damage to DNA. Surgery can create dysfunction, including blind gut loops that lead to absorption problems and loss of function of removed body parts. Radiation may damage end-organ function, for example, loss of potency in prostate cancer patients, pulmonary fibrosis, neurocognitive impairment, acceleration of atherosclerosis, and second cancers. Cancer chemotherapy may act as a carcinogen and has a kaleidoscope of other toxicities, as discussed in this chapter. Table 102–1 lists the long-term effects of treatment.

Table Graphic Jump Location
Table 102–1 Late Effects of Cancer Therapy 

The first goal of therapy is to eradicate or control the malignancy. Late treatment consequences are, indeed, testimony to the increasing success of such treatment. Their occurrence sharply underlines the necessity to develop more effective therapies with less long-term morbidity ...

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.


About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Subscription Options

AccessMedicine Full Site: One-Year Subscription

Connect to the full suite of AccessMedicine content and resources including more than 250 examination and procedural videos, patient safety modules, an extensive drug database, Q&A, Case Files, and more.

$995 USD
Buy Now

Pay Per View: Timed Access to all of AccessMedicine

24 Hour Subscription $34.95

Buy Now

48 Hour Subscription $54.95

Buy Now

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.